Business
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA conference - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 on track for Q2 2026; global confirmatory Phase 3 HARMONIA trial initiated - -
About this update from Dyne Therapeutics, Inc.
[{"type":"image","alt":"Dyne Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dyne Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k23yvwJif2jshK1r_uNGyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNw--/https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39","width":300,"height":91},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/k23yvwJif2jshK1r_uNGyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNw--/https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39","width":300,"height":91}},"lazy":false},{"type":"text","content":"- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -","length":152,"tagName":"p"},{"type":"text","content":"- Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA conference -","length":155,"tagName":"p"},{"type":"text","content":"- Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 on track for Q2 2026; global confirmatory Phase 3 HARMONIA trial initiated -","length":188,"tagName":"p"},{"type":"text","content":"- New preclinical data to be presented at ASGCT underscore differentiated capability of clinically validated FORCETM platform to cross the blood-brain barrier -","length":160,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the first quarter of 2026 and recent business highlights.","length":318,"tagName":"p"},{"type":"text","content":"“Following positive topline data late last year, we continue to ramp up activities to support a potential launch of z-rostudirsen in DMD in the first quarter of 2027,” said John Cox, president and chief executive officer of Dyne. “We are grateful to the FDA for a collaborative pre-BLA meeting, where we aligned on the contents of our planned BLA submission for U.S...